Adaptive Biotechnologies Corp
NASDAQ:ADPT
Adaptive Biotechnologies Corp
NASDAQ:ADPT
Price:
2.4 USD
2.78%
Market Closed
Updated:
Apr 20, 2024
P/B
Price to Book Value
Price to Book Value
1.1
Current
2.5
Median
2.4
Industry
Lower
than median
Lower
than industry value
Price to Book Value (P/B) ratio is a valuation multiple that measures the market's valuation of a company relative to its book value. The P/B ratio is only considered useful in practice when applied to capital-intensive businesses.
P/B
=1.1
Market Cap
/
348.2m
Book Value of Equity
308.4m
All Countries
| Market Cap | P/B | ||||
|---|---|---|---|---|---|
| US |
|
Adaptive Biotechnologies Corp
NASDAQ:ADPT
|
348.2m USD | 1.1 | |
| US |
|
Thermo Fisher Scientific Inc
NYSE:TMO
|
210.2B USD | 4.5 | |
| US |
|
Danaher Corp
NYSE:DHR
|
173.7B USD | 3.3 | |
| US |
|
IQVIA Holdings Inc
NYSE:IQV
|
41.3B USD | 6.8 | |
| KR |
|
Samsung Biologics Co Ltd
KRX:207940
|
55.6T KRW | 5.8 | |
| CH |
|
Lonza Group AG
SIX:LONN
|
36.2B CHF | 3.8 | |
| US |
|
Agilent Technologies Inc
NYSE:A
|
39B USD | 6.3 | |
| US |
|
West Pharmaceutical Services Inc
NYSE:WST
|
27.7B USD | 9.5 | |
| US |
|
Mettler-Toledo International Inc
NYSE:MTD
|
25.6B USD | -170.6 | |
| IE |
|
ICON PLC
NASDAQ:ICLR
|
23.8B USD | 2.6 | |
| FR |
|
Sartorius Stedim Biotech SA
PAR:DIM
|
18.5B EUR | 7 |
P/B Forward Multiples
Forward P/B multiple is a version of the P/B ratio that uses forecasted equity for the P/B calculation. 1-Year, 2-Years, and 3-Years forwards use equity forecasts for 1, 2, and 3 years ahead, respectively.
1-Year Forward
P/B
N/A
2-Years Forward
P/B
N/A
3-Years Forward
P/B
N/A
You don't have any saved screeners yet
